Back
TSND-201 for the Treatment for PTSD: Functional and Global Improvements from the Open-Label Portion of the IMPACT-1 Study (T36)
Poster Presentation

TSND-201 for the Treatment for PTSD: Functional and Global Improvements from the Open-Label Portion of the IMPACT-1 Study (T36)

American Society of Clinical Psychopharmacology (ASCP), May 2024.
View Presentation

Summary of poster presentation:

  • TSND-201 provided meaningful improvements on functioning and global measures of change.
  • Overall and across each domain of the Sheehan Disability Scale (SDS), TSND-201 demonstrated rapid and robust improvements in functioning.
  • Improvement in functioning was consistent with the clinician-rated global improvements.

View Poster

News

The Latest From Transcend

Transcend Therapeutics Presents New Data At ASCP Demonstrating Improvements In Functioning And Sleep-Related Symptoms in PTSD Patients Treated with TSND-201 (Methylone) Read More
Press Release

Transcend Therapeutics Presents New Data At ASCP Demonstrating Improvements In Functioning And Sleep-Related Symptoms in PTSD Patients Treated with TSND-201 (Methylone)
TSND-201 for the Treatment for PTSD: Functional and Global Improvements from the Open-Label Portion of the IMPACT-1 Study (T36) Read More
Poster Presentation

TSND-201 for the Treatment for PTSD: Functional and Global Improvements from the Open-Label Portion of the IMPACT-1 Study (T36)
TSND-201 for the Treatment for PTSD: Improvement in Sleep-Related Outcomes from the Open-label Portion of the IMPACT-1 Study (W45) Read More
Poster Presentation

TSND-201 for the Treatment for PTSD: Improvement in Sleep-Related Outcomes from the Open-label Portion of the IMPACT-1 Study (W45)
TSND-201, a rapid-acting treatment for PTSD and other Central Nervous System (CNS) disorders (T89) Read More
Poster Presentation

TSND-201, a rapid-acting treatment for PTSD and other Central Nervous System (CNS) disorders (T89)
Learn More